Adjustments to Current Assets
Adjustments to Total Assets
Adjustments to Current Liabilities
Adjustments to Total Liabilities
Adjustments to Stockholders’ Equity
Adjustments to Capitalization Table
Adjustments to Revenues
Adjustments to Reported Income

Moderna Inc., adjusted current assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Current assets	10,325)	13,431)	16,071)	6,298)	1,129)
Adjustments
Add: Wholesalers chargebacks, discounts and fees	692)	—)	—)	—)	—)
After Adjustment
Adjusted current assets	11,017)	13,431)	16,071)	6,298)	1,129)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Moderna Inc., adjusted total assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total assets	18,426)	25,858)	24,669)	7,337)	1,589)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Wholesalers chargebacks, discounts and fees	692)	—)	—)	—)	—)
Less: Deferred tax assets²	81)	982)	326)	—)	—)
After Adjustment
Adjusted total assets	19,037)	24,876)	24,343)	7,337)	1,589)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Deferred tax assets. See details »

Download chart

Moderna Inc., adjusted current liabilities

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Current liabilities	3,015)	4,923)	9,128)	4,389)	143)
Adjustments
Less: Deferred revenue, current	568)	2,038)	6,253)	3,867)	63)
After Adjustment
Adjusted current liabilities	2,447)	2,885)	2,875)	522)	80)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Moderna Inc., adjusted total liabilities

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total liabilities	4,572)	6,735)	10,524)	4,775)	415)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Less: Deferred tax liabilities²	15)	—)	—)	—)	—)
Less: Deferred revenue	651)	2,711)	6,868)	4,045)	202)
After Adjustment
Adjusted total liabilities	3,906)	4,024)	3,656)	731)	212)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Deferred tax liabilities. See details »

Download chart

Moderna Inc., adjusted stockholders’ equity

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Stockholders’ equity	13,854)	19,123)	14,145)	2,561)	1,175)
Adjustments
Less: Net deferred tax assets (liabilities)¹	66)	982)	326)	—)	—)
Add: Wholesalers chargebacks, discounts and fees	692)	—)	—)	—)	—)
Add: Deferred revenue	651)	2,711)	6,868)	4,045)	202)
After Adjustment
Adjusted stockholders’ equity	15,131)	20,852)	20,687)	6,606)	1,377)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Net deferred tax assets (liabilities). See details »

Download chart

Moderna Inc., adjusted capitalization table

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Financing lease liabilities, current	—)	161)	165)	24)	—)
Financing lease liabilities, non-current	575)	912)	599)	110)	39)
Total reported debt	575)	1,073)	764)	134)	39)
Stockholders’ equity	13,854)	19,123)	14,145)	2,561)	1,175)
Total reported capital	14,429)	20,196)	14,909)	2,696)	1,213)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Operating lease liabilities, current²	25)	35)	46)	6)	4)
Add: Operating lease liabilities, non-current³	643)	92)	106)	97)	94)
Adjusted total debt	1,243)	1,200)	916)	238)	136)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	66)	982)	326)	—)	—)
Add: Wholesalers chargebacks, discounts and fees	692)	—)	—)	—)	—)
Add: Deferred revenue	651)	2,711)	6,868)	4,045)	202)
Adjusted stockholders’ equity	15,131)	20,852)	20,687)	6,606)	1,377)
After Adjustment
Adjusted total capital	16,374)	22,052)	21,603)	6,844)	1,513)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Operating lease liabilities, current. See details »

³ Operating lease liabilities, non-current. See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

Moderna Inc., adjusted net product sales

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Net product sales	6,671)	18,435)	17,675)	200)	—)
Adjustment
Add: Increase (decrease) in deferred revenue	(2,060)	(4,157)	2,824)	3,842)	(72)
After Adjustment
Adjusted net product sales	4,611)	14,278)	20,499)	4,042)	(72)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Download chart

Moderna Inc., adjusted net income (loss)

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Net income (loss)	(4,714)	8,362)	12,202)	(747)	(514)
Adjustments
Add: Deferred income tax expense (benefit)¹	901)	(578)	(296)	—)	(1)
Add: Increase (decrease) in wholesalers chargebacks, discounts and fees	692)	—)	—)	—)	—)
Add: Increase (decrease) in deferred revenue	(2,060)	(4,157)	2,824)	3,842)	(72)
Add: Other comprehensive income (loss), net of tax	247)	(346)	(27)	1)	3)
After Adjustment
Adjusted net income (loss)	(4,934)	3,281)	14,703)	3,096)	(584)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

¹ Deferred income tax expense (benefit). See details »

Download chart

Moderna Inc. (NASDAQ:MRNA)

Adjustments to Financial Statements

Adjustments to Current Assets

Adjustments to Total Assets

Adjustments to Current Liabilities

Adjustments to Total Liabilities

Adjustments to Stockholders’ Equity

Adjustments to Capitalization Table

Adjustments to Revenues

Adjustments to Reported Income